Cancer Pain and Symptom Management: Drug Therapy

  • Jane Pruemer
  • Michelle Rockey
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

The symptoms of pancreatic cancer are varied, based upon the location of the disease. However, these symptoms are almost always caused by mass effect of the tumor compressing the vasculature, lymphatics, or other organs rather than disruption of exocrine or endocrine pancreatic function. Classic symptoms of pancreatic cancer include pain, jaundice, and weight loss (Table 25.1) (1). Since early symptoms are usually nonspecific, they may go unrecognized for some time, and most pancreatic cancers are advanced at the time of diagnosis. In addition to the symptoms produced by the tumor itself, pancreatic cancer treatments are associated with significant complications. The following disease- and/or treatment-related symptoms are reviewed, along with strategies for their management: pain, nausea and vomiting, diarrhea, and constipation.


Pancreatic Cancer Neuropathic Pain Clin Oncol Cancer Pain Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DiMagno EP. 1992, Cancer of the pancreas and biliary tract. In: Winawer SJ (ed.) Management of gastrointestinal disease. Gower Medical Publishing, New York.Google Scholar
  2. 2.
    Molinari M, Helton WS, Espat NJ. 2001, Palliative strategies for locally advanced unresectable and metastatic pancreatic cancer. Surg Clin North Am 81: 651–666.CrossRefPubMedGoogle Scholar
  3. 3.
    Chong MJ, Bajwa ZH. 2003, Diagnosis and treatment of neuropathic pain. J Pain Symtpm Manage 25(5 Suppl):S4–S11.CrossRefGoogle Scholar
  4. 4.
    Woolf CJ, Salter MW. 2000, Neuronal plasticity: increasing the gain in pain. Science 288:1765–1769.CrossRefPubMedGoogle Scholar
  5. 5.
    Evans DB, Abbruzzese JL, Willett CG. 2001, Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (eds.) Cancer: principles and practice of oncology, 6th ed. Philadelphia, Lippincott Williams & Wilkins, 1126–1161.Google Scholar
  6. 6.
    Mercadante S, Arcuri E. 2004, Opioids and renal function. J Pain 5:2–19.CrossRefPubMedGoogle Scholar
  7. 7.
    Derby S, Chin J, Portenoy RK. 1998, Systemic opioid therapy for chronic cancer pain: practi-cal guidelines for converting drugs and routes of administration. CNS Drugs 9:99–109.CrossRefGoogle Scholar
  8. 8.
    Dworkin RH, Backonja M, Rowbotham MC, et al. 2003, Advances in neuropathic pain. Arch Neurol 60:1524–1534.CrossRefPubMedGoogle Scholar
  9. 9.
    Sills GJ. 2006, The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6:108–113.CrossRefPubMedGoogle Scholar
  10. 10. Clinical Practice Guideline in Oncology v.2.2006 Antiemesis. NCCN, 2006 (Accessed 05/20/06).Google Scholar
  11. 11.
    Beckwith M, Mullin S. 2001, Prevention and management of chemotherapy-induced nausea and vomiting, part 1. Hospital Pharmacy 36:67–80.Google Scholar
  12. 12. Kris M, Hesketh P, Somerfield M, et al. 2006, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24, epub May 22.Google Scholar
  13. 13.
    Kris M, Baltzer L, Pisters K, et al. 1993, Enhancing the effectiveness of the specifc serotonin antagonists. Cancer 72(Suppl 11):3436–3642.CrossRefPubMedGoogle Scholar
  14. 14.
    Kris M, Pendergrass K, Navari R, et al. 1997, Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 15: 2135–2138.PubMedGoogle Scholar
  15. 15.
    Hesketh P, Navari R, Grote T, et al. 1996, Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14: 2242–2249.PubMedGoogle Scholar
  16. 16.
    Navari R, Gandara D, Hesketh P, et al. 1995, Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Gransistron Study Group. J Clin Oncol 13:1242–1248.Google Scholar
  17. 17.
    Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). 1998, Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia consensus conference. Ann Oncol 9: 811–819.CrossRefGoogle Scholar
  18. 18.
    Campora E, Merlini L, Pace M, et al. 1991, The incidence of narcotic-induced emesis. J Pain Symptom Manage 6:428–430.CrossRefPubMedGoogle Scholar
  19. 19.
    Asparasu R, McCoy R, Weber C, et al. 1999, Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J Pain Symptom Manage 18:280–288.CrossRefGoogle Scholar
  20. 20.
    Nicholson B. 2003, Responsible prescribing of opioids for the management of chronic pain. Drugs 63:17–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Mancini I, Bruera E, 1998, Constipation in advanced cancer patients. Support Care Cancer 6:356–364.CrossRefPubMedGoogle Scholar
  22. 22.
    Herndon M, Jackson K, Hallin P. 2002, Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 22:240–250.CrossRefPubMedGoogle Scholar
  23. 23.
    Pappagallo M. 2001, I ncidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S–18S.CrossRefPubMedGoogle Scholar
  24. 24.
    Grond S, Zech D, Diefenbach C, et al. 1994, Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372–382.CrossRefPubMedGoogle Scholar
  25. 25.
    Vanegas G, Ripamonti C, Sbanotto A, et al. 1998, Side of effects of morphine administration in cancer patients. Cancer Nurs 21:289–297.CrossRefPubMedGoogle Scholar
  26. 26.
    Glare P, Lickiss J. 1992, Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 7:369–371.CrossRefPubMedGoogle Scholar
  27. 27.
    Fallon M, Hanks G. 1999, Morphine, constipation and performance status in advanced cancer patients. Palliative Medicine 13:159–160.CrossRefPubMedGoogle Scholar
  28. 28.
    Sykes N. 1998, The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative Medicine 12:375–382.CrossRefPubMedGoogle Scholar
  29. 29.
    Ippoliti C. 1998, Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health-Syst Pharm 55:1573–1580.PubMedGoogle Scholar
  30. 30.
    Benson A, Ajani J, Calalano R, et al. 2004, Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918–2926.CrossRefPubMedGoogle Scholar
  31. 31.
    Arbucle R, Huber S, Zacker C. 2000, The consequences of diarrhea occurring during chemo-therapy for colorectal cancer: a retrospective study. Oncologist 5: 250–259.CrossRefGoogle Scholar
  32. 32.
    Schiller L. 1995, Review article: anti-diarrhoeal pharmacology and therapeutics. Aliment Pharmacol Ther 9:87–106.PubMedGoogle Scholar
  33. 33.
    Wadler S, Haynes H, Wiernik PH. 1995, Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13:222–226.PubMedGoogle Scholar
  34. 34.
    Miller R, Martenson J, Sargent D, et al. 1998, Acute treatment-related diarrhea during post-operative adjuvant therapy for high-risk rectal carcinoma. Int J Radiation Oncol Biol Phys 41:593–598.CrossRefGoogle Scholar
  35. 35.
    Gralla R, Osoba D, Kris M, et al. 1999, Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 17:2971–2994.PubMedGoogle Scholar
  36. 36.
    American Society of Health-System Pharmacists. 1999, ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729–764.Google Scholar
  37. 37.
    Koeller J, Aapro M, Gralla R, et al. 2002, Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10:519–522.CrossRefPubMedGoogle Scholar
  38. 38.
    Kris M, Hesketh P, Herrstedt J, et al. 2005, Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85–96.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Jane Pruemer
    • 1
  • Michelle Rockey
    • 2
  1. 1.James L. Winkle College of PharmacyUniversity of Cincinnati, Barrett Cancer CenterCincinnatiUSA
  2. 2.University HospitalCincinnatiUSA

Personalised recommendations